| gap-pubmed-20260410- | What determines whether BBB dysfunction causes or results from neuroinflammation | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does Piezo1's dynamic structural complexity affect drug binding and channel | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanotransduction pathways linking Piezo1 dysfunction to | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can Piezo1-targeted drugs achieve tissue-specific targeting given its widesp | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do platelet immune functions contribute to neuroinflammation and neurodegene | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which platelets interact with anti | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does elevated hippocampal soluble Aβ from meprin β not produce detectable be | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the hippocampal vulnerability to meprin β-mediated Aβ elev | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can therapeutic interventions restore oligodendrogenesis capacity in aged brains | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do Olig2+/Nestin+ cells show reduced proliferation while Olig2+/PDGFRα+ cell | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the age-related decline in OPC proliferation | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether environmental factors cause tauopathy versus other neuro | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do most disease-modifying therapies targeting tau and Aβ pathology consisten | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms determine tau isoform specificity and cellular targeting in diff | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why has quercetin's potential in GBM treatment been inadequately explored despit | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What are the specific mechanisms by which quercetin overcomes drug resistance in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | Why does CRY1 show opposite associations with myelin integrity compared to other | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does glymphatic dysfunction causally mediate the relationship between poor s | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link circadian gene expression to regional myelin vuln | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do structural differences in STT3A versus STT3B catalytic subunits mechanist | open | 0.56 | 0.00 | 2026-04-10 | 0 | | protein-folding-and-neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine the distinct substrate affinities of OST-A v | open | 0.64 | 0.00 | 2026-04-10 | 0 | | protein-folding-and-neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms govern TOM-αSyn interactions and their downst | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does αSyn become pathologically accumulated in PD despite not being upregula | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the stepwise biological mechanisms of αSyn misimport into mitochondria | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the cell-type-specific mitochondrial phenotypes associated with | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ApoE4-induced fatty acid oxidation deficiency in astrocytes mechanistic | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms cause ApoE4 to specifically impair fatty acid transpor | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can therapeutic approaches be tailored to the unique neurobiological feature | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific biomarkers can distinguish depression-AD comorbidity from either c | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific causal mechanisms underlying the bidirectional relationshi | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does microglial C1q production contribute to chronic neuronal loss in the th | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does C1q expression increase specifically in the corticothalamic system afte | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link C1q upregulation to sleep spindle disruption and | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the direct molecular targets of Geniposide that initiate BTK pathway mo | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does BTK, primarily known for B-cell signaling, regulate neuroinflammation i | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How functionally equivalent are iPSC-derived microglia to brain-resident microgl | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the differential ADP-Ca2+ response in microgl | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do retinal neurons internalize tau fibrils and what determines the efficienc | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive NaTPP to produce fewer but longer fibrils compar | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do NaTPP-induced fibrils show initially low cytotoxicity but cause delayed s | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can LRRK2 kinase inhibitors be designed to avoid safety liabilities in non-n | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the cell type-specific mechanisms by which LRRK2 kinase activity causes | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do environmental factors and lifestyle specifically interact with epigenetic | open | 0.78 | 0.00 | 2026-04-10 | 0 | | environmental-neuroscience |
| gap-pubmed-20260410- | What are the specific mechanisms by which epigenetic alterations cause brain dis | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroepigenetics |
| gap-pubmed-20260410- | What determines the balance between pyroptosis, apoptosis, and necroptosis withi | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do influenza viral proteins M2, NS1, and PB1-F2 mechanistically regulate ZBP | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the precise molecular mechanisms by which ZBP1 recruits RIPK3 and caspa | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do memory deficits from GABAergic LRP1 deletion only emerge at 32 weeks but | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does LRP1 in GABAergic neurons maintain excitatory/inhibitory balance to pre | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms link LRP1 deficiency in GABAergic neurons to hippocamp | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |